Two COVID-19 vaccine products for young children are nearing the final stages of the Emergency Use Authorization (EUA) process. Pfizer-BioNTech is submitting data on a THREE-dose primary series for a vaccine for children ages six months through FOUR years of age (6m–4y). Moderna is submitting data on a TWO-dose primary series for children ages six months through FIVE years of age (6m–5 y). The authorization is a multi-step clinical and regulatory process, and no vaccine can be administered until the final recommendation is issued by the CDC Director, Dr. Walensky. In preparation, this guidance includes details about BOTH products.
top of page
Search
Recent Posts
See AllWe’ve been hearing about vaccines for years now, but you rarely get all the facts you need. There’s a new online crash course by Voices for Vaccines that will teach you practical information about vac
The NYS Office of Mental Health (OMH) announces the additional availability of funds to support the implementation of HealthySteps. Our goal is to promote an intentional focus on prevention activitie
bottom of page